CL2014002706A1 - Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación. - Google Patents

Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.

Info

Publication number
CL2014002706A1
CL2014002706A1 CL2014002706A CL2014002706A CL2014002706A1 CL 2014002706 A1 CL2014002706 A1 CL 2014002706A1 CL 2014002706 A CL2014002706 A CL 2014002706A CL 2014002706 A CL2014002706 A CL 2014002706A CL 2014002706 A1 CL2014002706 A1 CL 2014002706A1
Authority
CL
Chile
Prior art keywords
phospholipid
pain
joint
treatment
active agent
Prior art date
Application number
CL2014002706A
Other languages
English (en)
Inventor
Richard Wolf Garraway
Michael Earl
Saruhan Yurdakul
Nicolas Baverstock
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Publication of CL2014002706A1 publication Critical patent/CL2014002706A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2014002706A 2012-04-12 2014-10-08 Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación. CL2014002706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206486.1A GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof

Publications (1)

Publication Number Publication Date
CL2014002706A1 true CL2014002706A1 (es) 2015-04-24

Family

ID=46208989

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002706A CL2014002706A1 (es) 2012-04-12 2014-10-08 Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.

Country Status (26)

Country Link
US (3) US20150065461A1 (es)
EP (1) EP2836203B1 (es)
JP (1) JP2015512926A (es)
KR (1) KR102204725B1 (es)
CN (1) CN104363894B (es)
AU (1) AU2013246822A1 (es)
BR (1) BR112014025507B1 (es)
CA (1) CA2870111A1 (es)
CL (1) CL2014002706A1 (es)
CO (1) CO7141430A2 (es)
DK (1) DK2836203T3 (es)
EA (1) EA039626B1 (es)
ES (1) ES2916803T3 (es)
GB (2) GB201206486D0 (es)
HR (1) HRP20220700T1 (es)
HU (1) HUE058972T2 (es)
IL (1) IL234862A0 (es)
IN (1) IN2014DN08259A (es)
LT (1) LT2836203T (es)
MX (1) MX2014012198A (es)
PH (1) PH12014502079A1 (es)
PL (1) PL2836203T3 (es)
PT (1) PT2836203T (es)
SG (1) SG11201406251VA (es)
SI (1) SI2836203T1 (es)
WO (1) WO2013153221A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
WO2011022707A1 (en) 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
HRP20211669T1 (hr) 2015-06-30 2022-02-18 Sequessome Technology Holdings Limited Multifazni pripravci
IL301801B1 (en) * 2017-08-22 2024-06-01 Moebius Medical Ltd Liposomal formulations for joint lubrication
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CN110314137B (zh) * 2018-03-30 2022-04-05 北京泰德制药股份有限公司 一种含有脂质囊泡的冻干制剂
KR20230041954A (ko) 2021-09-17 2023-03-27 서울대학교산학협력단 골관절염 예방 또는 치료용 약학 조성물 및 건강기능식품

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509202A (ja) * 1992-07-08 1996-10-01 ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポソーム、それを調製する方法及び薬調製におけるその用途
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
PL367337A1 (en) * 2001-05-31 2005-02-21 Pharmacia Corporation Skin-permeable selective cyclooxygenase-2 inhibitor composition
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
US7115666B2 (en) * 2002-10-15 2006-10-03 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
WO2008038292A2 (en) * 2006-09-28 2008-04-03 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
ES2682075T3 (es) * 2009-06-03 2018-09-18 Sequessome Technology Holdings Limited Formulaciones para el tratamiento de dolor de tejido profundo
WO2011022707A1 (en) * 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
CN108130373A (zh) * 2013-03-13 2018-06-08 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物

Also Published As

Publication number Publication date
BR112014025507A2 (pt) 2017-08-08
KR20150008869A (ko) 2015-01-23
EP2836203B1 (en) 2022-03-09
EA039626B1 (ru) 2022-02-17
BR112014025507B1 (pt) 2022-01-04
CN104363894A (zh) 2015-02-18
DK2836203T3 (da) 2022-06-07
PT2836203T (pt) 2022-06-15
JP2015512926A (ja) 2015-04-30
ES2916803T3 (es) 2022-07-06
MX2014012198A (es) 2015-06-04
LT2836203T (lt) 2022-06-10
EP2836203A1 (en) 2015-02-18
US20150065461A1 (en) 2015-03-05
HRP20220700T1 (hr) 2022-07-08
WO2013153221A1 (en) 2013-10-17
GB201206486D0 (en) 2012-05-30
SI2836203T1 (sl) 2022-07-29
PH12014502079A1 (en) 2014-12-10
EA201491583A1 (ru) 2015-05-29
IL234862A0 (en) 2014-12-31
CN104363894B (zh) 2016-11-23
SG11201406251VA (en) 2014-10-30
CA2870111A1 (en) 2013-10-17
HUE058972T2 (hu) 2022-09-28
PL2836203T3 (pl) 2022-07-11
AU2013246822A1 (en) 2014-10-16
CO7141430A2 (es) 2014-12-12
US20170128473A1 (en) 2017-05-11
KR102204725B1 (ko) 2021-01-19
GB2515439B (en) 2017-08-23
US20210393655A1 (en) 2021-12-23
IN2014DN08259A (es) 2015-05-15
GB201419074D0 (en) 2014-12-10
GB2515439A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
CL2014002706A1 (es) Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
CO6480985A2 (es) Formulaciones para el tratamiento del dolor tisular profundo
CL2015000499A1 (es) Uso de un agente farmacéuticamente aceptable que elimina el antígeno de superficie de la hepatitis b de la sangre y un segundo agente que estimula la función inmunitaria, para tratar hepatitis b o coinfección hepatitis b/hepatitis d; y composición que comprende ambos agentes.
AR097556A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
CL2015001869A1 (es) Composición inyectable acuosa de diclofenaco en una solucion de eter monoetilico de dietilenglicol y agua; metodo de preparacion; y uso en el tratamiento o prevencion del dolor y/o condiciones inflamatorias como dolor de cabeza, dolor de garganta, entre otras.
SG10201704712QA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MA50358A (fr) Sémaglutide en thérapie médicale
ZA201504783B (en) Cosmetic or dermatological composition comprising a merocyanine and a uva-screening agent of the amino-substituted 2-hydroxybenzophenone type and/or a hydrophilic organic uva-screening agent
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CO7240380A2 (es) Composiciones líquidas orales pediátricas que contienen nepadutant
ITUB20153104A1 (it) Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
EP3474840A4 (en) USE OF CYANOGLUCOSIDES AND PHARMACEUTICAL FORMULATIONS THEREOF IN THE TREATMENT OF DIABETES
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
HK1202250A1 (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
CL2015001970A1 (es) Una formulación liquida para el cuidado oral que comprende una mezcla de terpenos como principio activo